 |
|
|
| |
Simeprevir (TMC435) with peginterferon-α/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naαve patients: efficacy in patients with genotype 1b HCV in the QUEST-1 and -2 Phase III trials
|
| |
| |
Reported by Jules Levin
APASL March 12-15 2014
Brisbane, Australia
GJ Dore,1 IM Jacobson,2 GR Foster,3 M Fried,4 M Manns,5 P Marcellin,6 F Poordad,7 ES Affonso de Araujo,8 M Peeters,9 O Lenz,9 S Ouwerkerk-Mahadevan,9 G De La Rosa,10 R Kalmeijer,10 R Sinha,9 M Beumont-Mauviel9
1The Kirby Institute, University of New South Wales, Darlinghurst, NSW, Australia; 2Weill Cornell Medical College, New York, NY, USA; 3Queen Mary's, University of London, London, UK; 4University of North Carolina at Chapel Hill, NC, USA; 5Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany; 6Hopital Beaujon, Service d'Hepatologie, Clichy, France; 7Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 8Hospital das Clinicas of the University of Sao Paulo School of Medicine, Sao Paulo, Brazil; 9Janssen Infectious Diseases BVBA and Janssen Research & Development, Beerse, Belgium; 10Janssen Global Services, LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
